Scheduled versus Pro Re Nata dosing in the VIEW trials

Ophthalmology

Volumn 122, Issue 12, 2015, Pages 2497-2503

  Richard, Gisbert ^a   Monés, Jordi ^b   Wolf, Sebastian ^c   Korobelnik, Jean François ^d,e,f   Guymer, Robyn ^g   Goldstein, Michaella ^h   Norenberg, Christiane ⁱ   Sandbrink, Rupert ^i,j   Zeitz, Oliver ^a,i  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b HOSPITAL QUIRÓN   (Spain)

^c UNIVERSITY OF BERN   (Switzerland)

^d BORDEAUX UNIVERSITY HOSPITAL   (France)

^e UNIVERSITÉ DE BORDEAUX   (France)

^f INSERM   (France)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h TEL AVIV UNIVERSITY   (Israel)

ⁱ BAYER PHARMA AG   (Germany)

^j HEINRICH HEINE UNIVERSITY   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

ADULT; AGE RELATED MACULAR DEGENERATION; ARTICLE; CENTRAL RETINAL THICKNESS; CLINICAL TRIAL (TOPIC); DIABETIC RETINOPATHY; DISEASE ACTIVITY; DRUG DOSE COMPARISON; HUMAN; MAJOR CLINICAL STUDY; OPTICAL COHERENCE TOMOGRAPHY; POST HOC ANALYSIS; PRIORITY JOURNAL; THROMBOEMBOLISM; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL IMPAIRMENT; AGED; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; INTRAVITREAL DRUG ADMINISTRATION; MACULAR DEGENERATION; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RETREATMENT; RETROSPECTIVE STUDY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; RANIBIZUMAB; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETREATMENT; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84947996837     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2015.08.014     Document Type: Article

References (10)

1. D.M. Brown, P.K. Kaiser, M. Michels, and et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 2006 1432 1444
2. U. Chakravarthy, S.P. Harding, C.A. Rogers, and et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial Ophthalmology 119 2012 1399 1411
3. J.S. Heier, D.M. Brown, V. Chong, and et al. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration Ophthalmology 119 2012 2537 2548
4. P.J. Rosenfeld, D.M. Brown, J.S. Heier, and et al. Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431
5. D.F. Martin, M.G. Maguire, S.L. Fine, and et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results Ophthalmology 119 2012 1388 1398
6. B.G. Busbee, A.C. Ho, D.M. Brown, and et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration Ophthalmology 120 2013 1046 1056
7. H. Oubraham, S.Y. Cohen, S. Samimi, and et al. Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration Retina 31 2011 26 30
8. A.N. Economides, L.R. Carpenter, J.S. Rudge, and et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action Nat Med 9 2003 47 52
9. J. Holash, S. Davis, N. Papadopoulos, and et al. VEGF-Trap: a VEGF blocker with potent antitumor effects Proc Natl Acad Sci U S A 99 2002 11393 11398
10. U. Schmidt-Erfurth, P.K. Kaiser, J.F. Korobelnik, and et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies Ophthalmology 121 2014 193 201